Alex Zwierzynski
Medical · Auburn, NYNPI 1043826282
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by UCB, Inc. at 40.1% of the total. Reporting peaked in 2024 at $18,670 and has fallen 56.3% since, to $8,165 in 2025. Among medical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,086 payments — averaging $38.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$17K
- Lilly USA, LLC$5K
- AbbVie$4K
- Johnson & Johnson$3K
- LEO Pharma Inc.$2K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $10K from 19 others
What the payments were for
- Consulting fees$18,96046%
- Travel & lodging$3,1188%
- Food & beverage$18,66345%
- Education$5971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 65 | $16,594 |
| Lilly USA, LLC | 58 | $4,522 |
| AbbVie | 168 | $3,665 |
| Johnson & Johnson | 109 | $3,149 |
| LEO Pharma Inc. | 67 | $2,090 |
| E.r. Squibb & Sons, L.L.C. | 69 | $1,616 |
| Incyte Corporation | 91 | $1,549 |
| Novartis | 95 | $1,375 |
| Dermavant Sciences, Inc. | 86 | $1,243 |
| Sun Pharmaceutical Industries Inc. | 57 | $1,230 |
| Arcutis Biotherapeutics, Inc. | 17 | $894 |
| Regeneron Healthcare Solutions, Inc. | 30 | $774 |
| Pfizer | 47 | $759 |
| Amgen | 34 | $497 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 55 | $437 |
| Sanofi | 8 | $273 |
| Galderma Laboratories, L.p. | 13 | $209 |
| Boehringer Ingelheim | 6 | $120 |
| Neurelis, Inc. | 1 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Botanix SB Inc | 2 | $42 |
| Fresenius Kabi USA, LLC | 2 | $35 |
| Genentech USA, Inc. | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $21 |
| Organon | 3 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,338 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyriziRisankizumab-Rzaa | 29 | $611,041 |
| Dupixent PenDupilumab | 103 | $389,319 |
| Humira(Cf) PenAdalimumab | 24 | $304,258 |
| TremfyaGuselkumab | 19 | $253,865 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $243,873 |
| OtezlaApremilast | 25 | $149,082 |
| Dupixent SyringeDupilumab | 26 | $112,512 |
| RinvoqUpadacitinib | 11 | $69,328 |
| VtamaTapinarof | 19 | $26,050 |
| Tacrolimus | 87 | $11,229 |
| Ketoconazole | 121 | $2,437 |
| Clobetasol Propionate | 37 | $2,187 |
| Doxycycline Hyclate | 55 | $2,172 |
| Desonide | 12 | $2,133 |
| Doxycycline Monohydrate | 32 | $1,930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSkyrizi, Rinvoq | $3,665 | $680,36940 claims |
| Johnson & JohnsonTremfya | $3,149 | $253,86519 claims |
| AmgenOtezla | $497 | $149,08225 claims |
| Dermavant Sciences, Inc.Vtama | $1,243 | $26,05019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in Auburn
- Jessica TisciAuburn$15K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.